Osteoarthritis Drug Pipeline Analysis Report 2025
Description
Osteoarthritis (OA) is a degenerative joint disease characterized by the breakdown of cartilage, leading to pain, stiffness, and reduced mobility. It accounts for around 528 million cases globally. There is a significant unmet clinical need for better therapies to treat osteoarthritis, as current treatments, such as pain relievers and anti-inflammatory drugs, only provide limited relief. Furthermore, the growing focus on disease-modifying osteoarthritis drugs (DMOADs) and regenerative therapeutics is likely to support pipeline growth in the coming years, offering hope for more effective treatment options.
Report Coverage
The Osteoarthritis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into osteoarthritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for osteoarthritis. The osteoarthritis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The osteoarthritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with osteoarthritis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to osteoarthritis.
Osteoarthritis Drug Pipeline Outlook
Osteoarthritis is a chronic degenerative joint disease caused by cartilage breakdown and inflammation, leading to joint pain, stiffness, and reduced mobility. The osteoarthritis drug pipeline focuses on disease-modifying osteoarthritis drugs (DMOADs), anti-inflammatory agents, and regenerative therapies aimed at slowing disease progression, reducing pain, and improving joint function.
Osteoarthritis treatment aims to alleviate pain and improve function. Common approaches include pain relievers, anti-inflammatory medications, corticosteroid injections, and physical therapy. In severe cases, joint replacement surgery may be necessary. Recent advancements in biologics and regenerative treatments also show promise in addressing the root causes of osteoarthritis.
Osteoarthritis Epidemiology
The osteoarthritis (OA) drug pipeline is evolving to address the high global burden of the disease. Osteoarthritis affects approximately 528 million people globally, with over 50 million cases in the United States. In the United Kingdom, knee osteoarthritis impacts 5.4 million people, while India reports a prevalence of 22% to 39%. This growing incidence underscores the urgent need for advanced therapeutics in the pipeline.
Osteoarthritis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of osteoarthritis drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total osteoarthritis clinical trials.
Osteoarthritis – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the osteoarthritis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, cell-based therapies, and peptide therapeutics. The osteoarthritis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for osteoarthritis.
Osteoarthritis Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the osteoarthritis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed osteoarthritis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in osteoarthritis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for osteoarthritis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of osteoarthritis drug candidates.
Drug: TG-C
The Phase 3 study, sponsored by Kolon TissueGene, Inc., aims to evaluate the efficacy and safety of TG-C in subjects with Kellgren/Lawrence Grade 2 or 3 osteoarthritis of the knee. The study, a randomized, double-blind, placebo-controlled trial, is expected to be completed by March 2026 with approximately 531 participants. It will assess both symptomatic relief and disease-modifying effects of TG-C, administered via intra-articular injection.
Drug: LNA043 Dosing Regimen A
The study sponsored by Novartis Pharmaceuticals aims to examine the efficacy, safety, and tolerability of LNA043 in patients with knee osteoarthritis. The Phase 2 study will evaluate the optimal dosing regimen of LNA043. The study is expected to be completed by October 2027, with 583 participants enrolled.
Drug: SAR446959
The drug SAR446959, sponsored by Sanofi, is currently undergoing a Phase 1 study to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with knee osteoarthritis. The study aims to evaluate the effects of ascending single intra-articular doses of SAR446959. It is expected to be completed by December 2025, with an estimated 32 participants involved.
Reasons to Buy This Report
The Osteoarthritis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for osteoarthritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into osteoarthritis collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Osteoarthritis – Pipeline Insight Report
Osteoarthritis Therapeutics Market
Global Clinical Trials Market
Report Coverage
The Osteoarthritis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into osteoarthritis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for osteoarthritis. The osteoarthritis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The osteoarthritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with osteoarthritis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to osteoarthritis.
Osteoarthritis Drug Pipeline Outlook
Osteoarthritis is a chronic degenerative joint disease caused by cartilage breakdown and inflammation, leading to joint pain, stiffness, and reduced mobility. The osteoarthritis drug pipeline focuses on disease-modifying osteoarthritis drugs (DMOADs), anti-inflammatory agents, and regenerative therapies aimed at slowing disease progression, reducing pain, and improving joint function.
Osteoarthritis treatment aims to alleviate pain and improve function. Common approaches include pain relievers, anti-inflammatory medications, corticosteroid injections, and physical therapy. In severe cases, joint replacement surgery may be necessary. Recent advancements in biologics and regenerative treatments also show promise in addressing the root causes of osteoarthritis.
Osteoarthritis Epidemiology
The osteoarthritis (OA) drug pipeline is evolving to address the high global burden of the disease. Osteoarthritis affects approximately 528 million people globally, with over 50 million cases in the United States. In the United Kingdom, knee osteoarthritis impacts 5.4 million people, while India reports a prevalence of 22% to 39%. This growing incidence underscores the urgent need for advanced therapeutics in the pipeline.
Osteoarthritis – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of osteoarthritis drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal antibodies
- Gene Therapies
- Cell-based Therapies
- Peptide Therapeutics
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total osteoarthritis clinical trials.
Osteoarthritis – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the osteoarthritis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, cell-based therapies, and peptide therapeutics. The osteoarthritis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for osteoarthritis.
Osteoarthritis Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the osteoarthritis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed osteoarthritis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in osteoarthritis clinical trials:
- Kolon TissueGene, Inc.
- Cytonics Corporation
- Shin Poong Pharmaceutical Co., Ltd.
- Grunenthal
- Sanofi
- Novartis Pharmaceuticals
- VivaTech International, Inc.
- Amzell
- Pacira Pharmaceuticals, Inc.
- Rion Inc.
- Taiwan Bio Therapeutics Inc.
- Kangstem Biotech Co., Ltd.
- Anterogen Co., Ltd.
- Eli Lilly and Company
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for osteoarthritis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of osteoarthritis drug candidates.
Drug: TG-C
The Phase 3 study, sponsored by Kolon TissueGene, Inc., aims to evaluate the efficacy and safety of TG-C in subjects with Kellgren/Lawrence Grade 2 or 3 osteoarthritis of the knee. The study, a randomized, double-blind, placebo-controlled trial, is expected to be completed by March 2026 with approximately 531 participants. It will assess both symptomatic relief and disease-modifying effects of TG-C, administered via intra-articular injection.
Drug: LNA043 Dosing Regimen A
The study sponsored by Novartis Pharmaceuticals aims to examine the efficacy, safety, and tolerability of LNA043 in patients with knee osteoarthritis. The Phase 2 study will evaluate the optimal dosing regimen of LNA043. The study is expected to be completed by October 2027, with 583 participants enrolled.
Drug: SAR446959
The drug SAR446959, sponsored by Sanofi, is currently undergoing a Phase 1 study to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with knee osteoarthritis. The study aims to evaluate the effects of ascending single intra-articular doses of SAR446959. It is expected to be completed by December 2025, with an estimated 32 participants involved.
Reasons to Buy This Report
The Osteoarthritis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for osteoarthritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into osteoarthritis collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Osteoarthritis – Pipeline Insight Report
- Which companies/institutions are leading the osteoarthritis drug development?
- What is the efficacy and safety profile of osteoarthritis pipeline drugs?
- Which company is leading the osteoarthritis pipeline development activities?
- What is the current osteoarthritis commercial assessment?
- What are the opportunities and challenges present in the osteoarthritis drug pipeline landscape?
- What is the efficacy and safety profile of osteoarthritis pipeline drugs?
- Which company is conducting major trials for osteoarthritis drugs?
- Which companies/institutions are involved in osteoarthritis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in osteoarthritis?
Osteoarthritis Therapeutics Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Osteoarthritis
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Osteoarthritis
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Osteoarthritis: Epidemiology Snapshot
- 5.1 Osteoarthritis Incidence by Key Markets
- 5.2 Osteoarthritis – Patients Seeking Treatment in Key Markets
- 6 Osteoarthritis: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Osteoarthritis: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Osteoarthritis, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Osteoarthritis Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Osteoarthritis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Biological: TG-C
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: RTX-GRT7039
- 10.2.3 Drug: ZILRETTA
- 10.2.4 Other Drugs
- 11 Osteoarthritis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: LNA043 Dosing Regimen A
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: RHH646
- 11.2.3 Drug: QUC398
- 11.2.4 Other Drugs
- 12 Osteoarthritis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: SAR446959
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Biological: ANT-301
- 12.2.3 Other Drugs
- 13 Osteoarthritis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Biological: Cell-free Stem Cell-derived Extract Formulation (CCM)
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Osteoarthritis, Key Drug Pipeline Companies
- 14.1 Kolon TissueGene, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Cytonics Corporation
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Shin Poong Pharmaceutical Co. Ltd.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Grunenthal
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Sanofi
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Novartis Pharmaceuticals
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 VivaTech International, Inc.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Amzell
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Pacira Pharmaceuticals, Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Rion Inc.
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Taiwan Bio Therapeutics Inc.
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 14.12 Kangstem Biotech Co., Ltd.
- 14.12.1 Company Snapshot
- 14.12.2 Pipeline Product Portfolio
- 14.12.3 Financial Analysis
- 14.12.4 Recent News and Developments
- 14.13 Anterogen Co., Ltd.
- 14.13.1 Company Snapshot
- 14.13.2 Pipeline Product Portfolio
- 14.13.3 Financial Analysis
- 14.13.4 Recent News and Developments
- 14.14 Eli Lilly and Company
- 14.14.1 Company Snapshot
- 14.14.2 Pipeline Product Portfolio
- 14.14.3 Financial Analysis
- 14.14.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
